BioSpace News Archive

NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced they have submitted a De Novo Classification Request to the U.S. Food and Drug Administration (FDA) for the company’s First to Know™ at-home syphilis test.

ICON plc, a world-leading clinical research organization powered by healthcare intelligence, announced its financial guidance for the year ending December 31, 2024.

Hyperfine, Inc. announced the launch of the AI-powered eighth generation of Swoop® system software.

HistoSonics, Inc., (www.histosonics.com), developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the treatment of the first patient in its pivotal #HOPE4KIDNEY Trial.

Axena Health, Inc. has signed agreements with four leading distributors to streamline access to the Leva® Pelvic Health System.

NovaBay Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova branded products by Sonoma in the European Union.

MimiVax, Inc., a biotechnology company focused on the development of SurVaxM, a survivin-targeted vaccine therapy for glioblastoma and other cancers, announced new investments from the venture philanthropy arms of leading brain tumor patient organizations, VC, private and existing investors.

Multiply Labs and Fedegari Group Collaborate to Add Sterilization to Automated Cell Therapy Manufacturing for Eliminating Contamination Risks.

Adimab, LLC today announced that 12 new partner programs entered clinical development in 2023.

Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.